The ACTIVE trial
In the 18-month ACTIVE trial in 2,463 postmenopausal women with osteoporosis, new vertebral fractures occurred less often with abaloparatide than with placebo, as they did in the open-label teriparatide reference group. The estimated non-vertebral fracture rate was lower with abaloparatide than with placebo, and bone mineral density rose more with abaloparatide (all P under .001). Hypercalcaemia (raised blood calcium) was less frequent with abaloparatide than with teriparatide: 3.4% versus 6.4% (P = .006).
- Study type
- Human trial
- Population
- 2,463 postmenopausal women with osteoporosis (mean age 69; 28 sites in 10 countries); phase 3, double-blind versus placebo, with an open-label teriparatide reference arm.
- Source
- 1 Miller et al., 2016
Limitation: The teriparatide arm was open-label and was a reference comparator, not a powered head-to-head test.
Limitations in full
The teriparatide arm was open-label and was a reference comparator, not a powered head-to-head test. Fracture percentages sit in the full paper's tables; only the direction and the hypercalcaemia figures are quoted from the abstract read on 2026-11-14.